Alievio is a cutting-edge brand that aims to revolutionize the way we treat glaucoma. As the leading cause of blindness worldwide, glaucoma affects over 64 million people globally, a number that is projected to increase in the coming years. Unfortunately, there is currently no cure for glaucoma, but Alievio is developing an innovative solution.

Their flagship product, Sollevio, is the world's first personalized glaucoma treatment designed to halt vision loss. By targeting intraocular pressure (IOP), which is a key factor in glaucoma progression, Sollevio aims to slow down or even stop the damaging effects on the optic nerve. The team behind Alievio consists of highly skilled professionals, including Chief Scientific Officer, Lucinda Camras, PhD, and Chief Medical Officer, Sanjay Asrani, MD, both renowned experts in the field of ophthalmology.

With their extensive experience and expertise, Alievio is set to change the landscape of glaucoma treatment. If you or a loved one is living with glaucoma, Alievio is dedicated to providing innovative solutions to preserve your vision and improve your quality of life. Contact Alievio today to learn more about their groundbreaking products and pioneering approach